By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Edge Therapeutics 

NJIT-EDC Biotechnology Incubator
139 South Street, Suite 102
New Providence  New Jersey  07974  U.S.A.
Phone: 800-208-EDGE Fax: 800-208-3433



Company News
Edge Therapeutics Announces Publication Of Phase I/II Data On EG-1962 For The Treatment Of Aneurysmal Subarachnoid Hemorrhage In Peer-Reviewed Medical Journal, Stroke 12/12/2016 8:05:35 AM
Edge Therapeutics Reports Third Quarter Financial Results 11/1/2016 11:02:59 AM
Edge Therapeutics To Host Conference Call On November 1, 2016 To Discuss Third Quarter Financial Results 10/25/2016 8:18:02 AM
Edge Therapeutics Appoints Chief Operating Officer And Makes Inducement Grant Under NASDAQ Rule 5635(c)(4) 10/17/2016 7:30:03 AM
Edge Therapeutics To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series And Participate In Additional Investor Conferences In September 9/8/2016 8:11:45 AM
Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting The Potential Clinical And Health Economic Impact Of EG-1962 In Aneurysmal Subarachnoid Hemorrhage 9/7/2016 10:09:08 AM
Edge Therapeutics To Present Additional Data From Phase I/II NEWTON Study Of EG-1962 At Two Scientific Conferences In September 9/2/2016 8:19:51 AM
Edge Therapeutics Reports Second Quarter Financial Results And Recent Highlights 8/3/2016 10:21:38 AM
Edge Therapeutics Announces Closing Of $20 Million Debt Facility With Hercules Capital 8/2/2016 8:34:54 AM
Edge Therapeutics Announces First Patient Treated In Phase III NEWTON 2 Study Of EG-1962 In Adult Patients With Aneurysmal Subarachnoid Hemorrhage 7/29/2016 8:12:17 AM